Clinical Development of Cabazitaxel for the Treatment of Castration-Resistant Prostate Cancer
Castration resistant prostate cancer has historically been considered chemotherapy insensitive. However, the approval of estramustine phosphate, mitoxantrone, and docetaxel, over the past few decades, has challenged this notion. Despite these advances, until recently, only docetaxel had been shown t...
Furkejuvvon:
| Váldodahkkit: | , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
SAGE Publishing
2011-01-01
|
| Ráidu: | Clinical Medicine Insights: Oncology |
| Liŋkkat: | https://doi.org/10.4137/CMO.S6566 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|